Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Cough Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Cough Overview | 10 | 1 |
| Pipeline Products for Cough Comparative Analysis | 11 | 1 |
| Cough Therapeutics under Development by Companies | 12 | 2 |
| Cough Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Cough Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Cough Products under Development by Companies | 19 | 1 |
| Cough Products under Investigation by Universities/Institutes | 20 | 1 |
| Cough Companies Involved in Therapeutics Development | 21 | 18 |
| Afferent Pharmaceuticals, Inc. | 21 | 1 |
| Alitair Pharmaceuticals, Inc. | 22 | 1 |
| Alveonix AG | 23 | 1 |
| AstraZeneca Plc | 24 | 1 |
| AusBio Ltd | 25 | 1 |
| Charleston Laboratories, Inc. | 26 | 1 |
| Conrig Pharma ApS | 27 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 28 | 1 |
| GlaxoSmithKline Plc | 29 | 1 |
| Glenmark Pharmaceuticals Ltd. | 30 | 1 |
| GW Pharmaceuticals Plc | 31 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 32 | 1 |
| Johnson &Johnson | 33 | 1 |
| NeRRe Therapeutics Ltd | 34 | 1 |
| Orbis Biosciences Inc | 35 | 1 |
| Patara Pharma, Inc. | 36 | 1 |
| Pila Pharma AB | 37 | 1 |
| Vernalis Plc | 38 | 1 |
| Cough Therapeutics Assessment | 39 | 9 |
| Assessment by Monotherapy Products | 39 | 1 |
| Assessment by Combination Products | 40 | 1 |
| Assessment by Target | 41 | 2 |
| Assessment by Mechanism of Action | 43 | 2 |
| Assessment by Route of Administration | 45 | 2 |
| Assessment by Molecule Type | 47 | 1 |
| Drug Profiles | 48 | 33 |
| Ax-8 Drug Profile | 48 | 1 |
| benzonatate Drug Profile | 49 | 1 |
| CCP-05 Drug Profile | 50 | 1 |
| CCP-06 Drug Profile | 51 | 1 |
| CCP-07 Drug Profile | 52 | 1 |
| CCP-08 Drug Profile | 53 | 1 |
| CLAT-313 Drug Profile | 54 | 1 |
| codeine + guaifenesin Drug Profile | 55 | 1 |
| cromolyn sodium Drug Profile | 56 | 1 |
| DWJ-1340 Drug Profile | 57 | 1 |
| GRC-17536 Drug Profile | 58 | 2 |
| GSK-2339345 Drug Profile | 60 | 1 |
| guaifenesin + hydrocodone Drug Profile | 61 | 1 |
| guaifenesin ER Drug Profile | 62 | 1 |
| JNJ-39729209 Drug Profile | 63 | 1 |
| lesogaberan Drug Profile | 64 | 1 |
| levodropropizine CR Drug Profile | 65 | 1 |
| MD-990 Drug Profile | 66 | 1 |
| MK-7264 Drug Profile | 67 | 4 |
| NEO-5937 Drug Profile | 71 | 1 |
| orvepitant maleate Drug Profile | 72 | 2 |
| S-1226 Drug Profile | 74 | 2 |
| Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders Drug Profile | 76 | 1 |
| Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases Drug Profile | 77 | 1 |
| ST-015 Drug Profile | 78 | 1 |
| XEND-0501 Drug Profile | 79 | 2 |
| Cough Dormant Projects | 81 | 3 |
| Cough Discontinued Products | 84 | 1 |
| Cough Product Development Milestones | 85 | 10 |
| Featured News &Press Releases | 85 | 1 |
| Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study | 85 | 1 |
| May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference | 85 | 2 |
| May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors | 87 | 1 |
| Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference | 88 | 1 |
| Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study | 88 | 1 |
| Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study | 88 | 1 |
| Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study | 89 | 1 |
| Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing | 89 | 1 |
| Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial | 90 | 1 |
| Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine | 91 | 1 |
| Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing | 91 | 1 |
| Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet | 91 | 2 |
| Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug | 93 | 1 |
| Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept | 93 | 1 |
| Apr 29, 2014: Second Product in Vernalis Cough Cold Pipeline Achieves Proof-of-Concept | 93 | 2 |
| Appendix | 95 | 2 |
| Methodology | 95 | 1 |
| Coverage | 95 | 1 |
| Secondary Research | 95 | 1 |
| Primary Research | 95 | 1 |
| Expert Panel Validation | 95 | 1 |
| Contact Us | 95 | 1 |
| Disclaimer | 96 | 1 |